1. Scrip
  2. >>Focus On Asia
  3. >>India

India Pharma Chiefs On Supply Chain Learnings From Auto Sector, New ‘PAGE’ On Skilling

 
• By Anju Ghangurde

Leaders from India’s top drug makers discuss efforts to operationalize a world-class skilling institute, backed by tie-ups with organizations like the PDA, ISPE and also taking a leaf out of the automobile industry’s book to build supply chain resilience. They also exuded confidence on moving up the innovation value chain.

L- R: Sathya Prathipati,, senior partner & lead, lifesciences practice (Asia), McKinsey & Co; Umang Vohra, global CEO& MD, Cipla; GV Prasad, co-chairman & MD, Dr Reddy's Labs; Nilesh Gupta, MD, Lupin; Dilip Shanghvi, MD, Sun Pharma; & Pankaj Patel, chairman, Zydus Lifesciences

US Food and Drug Administration (FDA) Commissioner Robert Califf appears to have contributed to nudging a pivotal effort to build biopharma’s talent pool in India and fostering a culture of manufacturing and quality excellence.

Pharma leaders at a recent summit indicated that discussions with the FDA Commissioner on his visit to the country helped fortify

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

More from Focus On Asia

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.